Skip to main navigation
Manage consent
Kronos Bio logoKronos Bio logo

Investor Relations

  • About Us
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • Map
    • Screen
    • Optimize and Validate
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Financials & Filings
      • Quarterly Results
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Investor & Media Contact
  • Careers
  • Contact
Menu

Investor Relations - Top Nav

  • About Us
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • Map
    • Screen
    • Optimize and Validate
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Financials & Filings
      • Quarterly Results
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Investor & Media Contact
  • Careers
  • Contact

News Releases

Apr 10, 2021
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021
Mar 31, 2021
Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.
Mar 26, 2021
Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors
Mar 23, 2021
Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
Mar 10, 2021
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Mar 04, 2021
Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)
Feb 25, 2021
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Feb 22, 2021
Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference
Jan 26, 2021
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

Contact

Headquarters

Kronos Bio, Inc.
1300 So. El Camino Real
Suite 300
San Mateo, CA 94402
+1 (650) 781-5200

Research Facility

Kronos Bio, Inc.
301 Binney Street
2nd Floor East
Cambridge, MA 02142

PARTNERING INQUIRIES

bd@kronosbio.com

MEDIA INQUIRIES

media@kronosbio.com

INVESTOR INQUIRIES

investor@kronosbio.com

EMPLOYMENT INQUIRIES

careers@kronosbio.com

 

  • Linkedin
  • Twitter
TOP

© 2021 All rights reserved. EU Privacy Contacts.